These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 18004747

  • 1. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
    Ellinger J, Haan K, Heukamp LC, Kahl P, Büttner R, Müller SC, von Ruecker A, Bastian PJ.
    Prostate; 2008 Jan 01; 68(1):42-9. PubMed ID: 18004747
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.
    Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, Kahl P, Perabo FG, Müller SC, von Ruecker A, Bastian PJ.
    J Urol; 2008 Jan 01; 179(1):346-52. PubMed ID: 18006010
    [Abstract] [Full Text] [Related]

  • 7. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance.
    Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N, Elandt K, Krainer M.
    Prostate; 2007 Mar 01; 67(4):427-32. PubMed ID: 17192910
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?
    Bernardini S, Miano R, Iori R, Finazzi-Agrò E, Palmieri G, Ballerini S, Angeloni C, Orlandi A, Bellincampi L, Cortese C, Federici G.
    Clin Chim Acta; 2004 Dec 01; 350(1-2):181-8. PubMed ID: 15530476
    [Abstract] [Full Text] [Related]

  • 10. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
    Chuang CK, Chu DC, Tzou RD, Liou SI, Chia JH, Sun CF.
    Cancer Detect Prev; 2007 Dec 01; 31(1):59-63. PubMed ID: 17291695
    [Abstract] [Full Text] [Related]

  • 11. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
    Bastian PJ, Ellinger J, Schmidt D, Wernert N, Wellmann A, Müller SC, von Rücker A.
    Eur J Med Res; 2004 Nov 29; 9(11):523-7. PubMed ID: 15649863
    [Abstract] [Full Text] [Related]

  • 12. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.
    Lin X, Asgari K, Putzi MJ, Gage WR, Yu X, Cornblatt BS, Kumar A, Piantadosi S, DeWeese TL, De Marzo AM, Nelson WG.
    Cancer Res; 2001 Dec 15; 61(24):8611-6. PubMed ID: 11751372
    [Abstract] [Full Text] [Related]

  • 13. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer.
    Ellinger J, Albers P, Perabo FG, Müller SC, von Ruecker A, Bastian PJ.
    J Urol; 2009 Jul 15; 182(1):324-9. PubMed ID: 19447423
    [Abstract] [Full Text] [Related]

  • 14. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D.
    Clin Cancer Res; 2005 Dec 01; 11(23):8321-5. PubMed ID: 16322291
    [Abstract] [Full Text] [Related]

  • 15. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
    Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH.
    J Pathol; 2007 Feb 01; 211(3):269-77. PubMed ID: 17139617
    [Abstract] [Full Text] [Related]

  • 16. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma.
    Chu DC, Chuang CK, Fu JB, Huang HS, Tseng CP, Sun CF.
    J Urol; 2002 Apr 01; 167(4):1854-8. PubMed ID: 11912447
    [Abstract] [Full Text] [Related]

  • 17. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators.
    Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R, Mueller SC, von Ruecker A.
    Int J Cancer; 2008 Jan 01; 122(1):138-43. PubMed ID: 17764114
    [Abstract] [Full Text] [Related]

  • 18. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma.
    Jerónimo C, Varzim G, Henrique R, Oliveira J, Bento MJ, Silva C, Lopes C, Sidransky D.
    Cancer Epidemiol Biomarkers Prev; 2002 May 01; 11(5):445-50. PubMed ID: 12010858
    [Abstract] [Full Text] [Related]

  • 19. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP, Harya NS, Hutzley J, Bacich DJ, Monzon FA, Chandran U, Dhir R, O'Keefe DS.
    Prostaglandins Other Lipid Mediat; 2007 Jan 01; 82(1-4):185-97. PubMed ID: 17164146
    [Abstract] [Full Text] [Related]

  • 20. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells.
    Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ.
    Oncogene; 2002 Feb 07; 21(7):1048-61. PubMed ID: 11850822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.